<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04863339</url>
  </required_header>
  <id_info>
    <org_study_id>20-2267</org_study_id>
    <nct_id>NCT04863339</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery</brief_title>
  <official_title>Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery: A Double-Blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is to determine the effect of Tranexamic Acid (TXA) on blood loss during&#xD;
      endoscopic pituitary surgery. The hypothesis of this study is that TXA will reduce blood loss&#xD;
      during surgery compared to a placebo. To answer this hypothesis, the investigators are&#xD;
      conducting a randomized controlled trial in which half of participants will receive TXA and&#xD;
      half will receive placebo (saline) in a double blind fashion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants randomized to receive the investigational product vs placebo during a single study encounter.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The only staff with access to randomization codes will be our study statistician who created the randomization table and our investigational drug services pharmacy who is preparing the investigational product.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Blood Loss</measure>
    <time_frame>Time between incision and surgical closure, an average of 3 to 3.5 hours</time_frame>
    <description>Blood loss measured in mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra-operative Surgical Visibility - Wormald Scale Score</measure>
    <time_frame>Duration of operation, up to 4 hours</time_frame>
    <description>Wormald scale (0-10):&#xD;
The Wormald grading scale is a validated grading tool to measure visual field quality during endoscopic endonasal procedures.&#xD;
Lower scores indicate less bleeding and better surgical visibility.&#xD;
0 = No bleeding (optimal)&#xD;
= 1-2 points of blood ooze&#xD;
= 3-4 points of ooze&#xD;
= 5-6 points of ooze&#xD;
= 7-8 points of ooze&#xD;
= 9-10 points of ooze&#xD;
= &gt;10 points of ooze, obscuring field&#xD;
= Mild field bleeding with slow post-nasal accumulation&#xD;
= Moderate field bleeding with moderate post-nasal accumulation&#xD;
= Moderate-severe field bleeding with rapid post-nasal accumulation&#xD;
= Severe bleeding (worst) with nose filling rapidly&#xD;
These measurements will take place 6 times. During hours 1, 2, 3, and 4 of the surgery, as well as during sphenoidotomy and durotomy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Venous Thromboembolism</measure>
    <time_frame>from time of intervention administration through 1 week after surgery</time_frame>
    <description>Absolute number of incident venous thromboembolism</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Duration of Surgery</measure>
    <time_frame>Time between incision and surgical closure, an average of 3 to 3.5 hours</time_frame>
    <description>Measured in hours</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Pituitary Tumor</condition>
  <condition>Blood Loss</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Tranexamic Acid arm will receive a dose of Tranexamic Acid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the placebo arm will receive a saline placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>Single preoperative dose of 1 gram of Tranexamic Acid in 100 mL of saline given 0-30 minutes prior to surgery.</description>
    <arm_group_label>Tranexamic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single preoperative dose of 100 mL of saline placebo given 0-30 minutes prior to surgery.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Undergoing endoscopic pituitary surgery at UNC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clival invasion&#xD;
&#xD;
          -  Giant pituitary tumor (&gt;4 cm)&#xD;
&#xD;
          -  Revision pituitary surgery&#xD;
&#xD;
          -  Prior sinus surgery&#xD;
&#xD;
          -  Lund McKay score &gt; 3&#xD;
&#xD;
          -  Active thromboembolic disease&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  Concomitant pro-thrombotic medications&#xD;
&#xD;
          -  Concomitant use of anti-coagulants or anti-platelet agents&#xD;
&#xD;
          -  Subarachnoid hemorrhage&#xD;
&#xD;
          -  History of severe hypersensitivity to Tranexamic Acid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brent Senior, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Chapel Hill</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brent Senior, MD</last_name>
    <phone>919-966-3344</phone>
    <email>Brent_Senior@med.unc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UNC Chapel Hil</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brent Senior, MD</last_name>
      <phone>919-966-3344</phone>
      <email>Brent_Senior@med.unc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, Cook L, Kawahara T, Perel P, Prieto-Merino D, Ramos M, Cairns J, Guerriero C. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013 Mar;17(10):1-79. doi: 10.3310/hta17100.</citation>
    <PMID>23477634</PMID>
  </reference>
  <reference>
    <citation>Ping WD, Zhao QM, Sun HF, Lu HS, Li F. Role of tranexamic acid in nasal surgery: A systemic review and meta-analysis of randomized control trial. Medicine (Baltimore). 2019 Apr;98(16):e15202. doi: 10.1097/MD.0000000000015202.</citation>
    <PMID>31008946</PMID>
  </reference>
  <reference>
    <citation>Heyns M, Knight P, Steve AK, Yeung JK. A Single Preoperative Dose of Tranexamic Acid Reduces Perioperative Blood Loss: A Meta-analysis. Ann Surg. 2021 Jan 1;273(1):75-81. doi: 10.1097/SLA.0000000000003793.</citation>
    <PMID>32224739</PMID>
  </reference>
  <reference>
    <citation>Jahanshahi J, Hashemian F, Pazira S, Bakhshaei MH, Farahani F, Abasi R, Poorolajal J. Effect of topical tranexamic acid on bleeding and quality of surgical field during functional endoscopic sinus surgery in patients with chronic rhinosinusitis: a triple blind randomized clinical trial. PLoS One. 2014 Aug 18;9(8):e104477. doi: 10.1371/journal.pone.0104477. eCollection 2014.</citation>
    <PMID>25133491</PMID>
  </reference>
  <reference>
    <citation>Mebel D, Akagami R, Flexman AM. Use of Tranexamic Acid Is Associated with Reduced Blood Product Transfusion in Complex Skull Base Neurosurgical Procedures: A Retrospective Cohort Study. Anesth Analg. 2016 Feb;122(2):503-8. doi: 10.1213/ANE.0000000000001065.</citation>
    <PMID>26554461</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 23, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Neoplasms</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified individual data that supports the results will be shared beginning 12 to 24 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>12 to 24 months following publication</ipd_time_frame>
    <ipd_access_criteria>Requests for IPD can be made by email and will be reviewed by the PI. The study protocol and deidentified data can be provided for scientific analyses performed by physicians and researchers affiliated with academic institutions.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

